Literature DB >> 21590311

[Spondyloarthritides].

J Braun1, M Rudwaleit, J Sieper.   

Abstract

Spondyloarthritides are a group of inflammatory rheumatic disorders related by clinical symptoms and genetic predisposition; the most important subtype is ankylosing spondylitis. The other subtypes include psoriatic spondyloarthritis, after preceding infections, in association with chronic inflammatory bowel diseases, and undifferentiated spondyloarthritis. The most significant clinical symptoms are inflammatory back pain and peripheral, usually asymmetric oligoarthritis and enthesitis. The possibility of other organs being involved is typical to some extent and the frequency varies among the subtypes: particularly affected are the eyes, the skin, and the intestines. Less commonly aortic valve defects and arrhythmias occur. The strongest genetic factor is the MHC class I molecule HLA-B27, which is exhibited by 90% of the patients with ankylosing spondylitis. The diagnostic possibilities for early identification have improved in the last few years. Early determination of HLA-B27 and magnetic resonance imaging have contributed to this development. Conventional radiography still represents the gold standard in the diagnostic workup. New criteria for classification of axial and peripheral spondyloarthritis have recently become available and international recommendations for the management of ankylosing spondylitis were recently published.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21590311     DOI: 10.1007/s00108-010-2766-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  35 in total

1.  Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis--a population-based survey.

Authors:  Jane Zochling; Martin H J Bohl-Bühler; Xenofon Baraliakos; Ernst Feldtkeller; Jürgen Braun
Journal:  Clin Rheumatol       Date:  2006-03-10       Impact factor: 2.980

2.  Prevalence of spondyloarthropathies in France: 2001.

Authors:  A Saraux; F Guillemin; P Guggenbuhl; C H Roux; P Fardellone; E Le Bihan; A Cantagrel; I Chary-Valckenaere; L Euller-Ziegler; R-M Flipo; R Juvin; J-M Behier; B Fautrel; C Masson; J Coste
Journal:  Ann Rheum Dis       Date:  2005-04-07       Impact factor: 19.103

3.  What is the most important outcome parameter in ankylosing spondylitis?

Authors:  J Braun; J Sieper
Journal:  Rheumatology (Oxford)       Date:  2008-09-16       Impact factor: 7.580

4.  Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study.

Authors:  Jürgen Braun; Robert Landewé; Kay-Geert A Hermann; John Han; Songkai Yan; Paul Williamson; Désirée van der Heijde
Journal:  Arthritis Rheum       Date:  2006-05

5.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Authors:  S van der Linden; H A Valkenburg; A Cats
Journal:  Arthritis Rheum       Date:  1984-04

6.  Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes.

Authors:  X Baraliakos; J Listing; M Rudwaleit; H Haibel; J Brandt; J Sieper; J Braun
Journal:  Ann Rheum Dis       Date:  2007-02-28       Impact factor: 19.103

7.  Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria.

Authors:  Martin Rudwaleit; Anke Metter; Joachim Listing; Joachim Sieper; Jürgen Braun
Journal:  Arthritis Rheum       Date:  2006-02

8.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

Authors:  M Rudwaleit; D van der Heijde; R Landewé; J Listing; N Akkoc; J Brandt; J Braun; C T Chou; E Collantes-Estevez; M Dougados; F Huang; J Gu; M A Khan; Y Kirazli; W P Maksymowych; H Mielants; I J Sørensen; S Ozgocmen; E Roussou; R Valle-Oñate; U Weber; J Wei; J Sieper
Journal:  Ann Rheum Dis       Date:  2009-03-17       Impact factor: 19.103

9.  Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.

Authors:  S Visvanathan; C Wagner; J C Marini; D Baker; T Gathany; J Han; D van der Heijde; J Braun
Journal:  Ann Rheum Dis       Date:  2007-07-20       Impact factor: 19.103

10.  Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis.

Authors:  S Visvanathan; D van der Heijde; A Deodhar; C Wagner; D G Baker; J Han; J Braun
Journal:  Ann Rheum Dis       Date:  2008-05-21       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.